Via Vaccine News Daily :
" The reason for the failure of a Phase II clinical trial of Intercell AG's Vaccine Enhancement Patch for H5N1 influenza could be a faulty hemagglutinin inhibition assay, a newly released report reveals.
The patch is administered alongside a single vaccine shot and is meant to support dose-sparing efforts should an influenza pandemic arise, BioWorld.com reports.The Phase II clinical trial was conducted under a $128 million contract with the U.S. Department of Health and Human Services.
Two different doses of H5N1 influenza vaccine were tested in 500 subjects. No difference was found in seroprotection rates between those who had received both the vaccine as well as the VEP and those who only received the vaccine."
No comments:
Post a Comment